The Alzheimer's Drug Discovery Foundation (ADDF) is a venture philanthropy organization dedicated to funding breakthrough research in academia and the biotech industry to find drugs for Alzheimer's disease. Founded in 1998 by Leonard A. and Ronald S. Lauder, the ADDF has awarded nearly $400 million to fund 792 Alzheimer's drug development, biomarker, and prevention programs in 21 countries.
| Fund Size | N/A USD |
| Stages Focus | Early-stage drug development, Pre-Seed, Seed, Series A |
| Sectors Focus | Biotechnology, Pharmaceuticals, Academia, Healthcare |
| Portfolio Size | 3 companies |
The ADDF's investment thesis revolves around accelerating the development of drugs to prevent, treat, and cure Alzheimer's disease by funding high-risk, high-reward research projects that are often overlooked by traditional funding sources.
Active team contains 10 members (0 partners, 4 founders).
The Alzheimer's Drug Discovery Foundation (ADDF) is a venture philanthropy organization dedicated to funding breakthrough research in academia and the biotech industry to find drugs for Alzheimer's disease.
The Alzheimer's Drug Discovery Foundation is located in New York, USA.
The founding date of Alzheimer's Drug Discovery Foundation is not publicly available.
Alzheimer's Drug Discovery Foundation is a venture capital firm.
Yes, Alzheimer's Drug Discovery Foundation invests in Biotechnology.
Yes, Alzheimer's Drug Discovery Foundation invests in Pharmaceuticals.
Yes, Alzheimer's Drug Discovery Foundation invests in Academia.
Yes, Alzheimer's Drug Discovery Foundation invests in Healthcare.
Yes, Alzheimer's Drug Discovery Foundation invests in Early-stage drug development.
Yes, Alzheimer's Drug Discovery Foundation invests in Pre-Seed.